69 results about "Antigen Targeting" patented technology

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The present invention provides neutralizing monoclonal antibodies targeting Nipah virus G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out three monoclonal antibodies that can specifically bind to NiV G protein. Antibody epitope competition experiments found that the S1E2 and SB10 monoclonal antibodies among these three antibodies recognize new epitopes of NiV G protein that have not been reported before. In vitro neutralization experiments have demonstrated that these three antibodies have high in vitro neutralizing activity, and can neutralize both NiV-M and NiV-B strains, with the characteristics of high expression and good stability, and can be used to prepare virus detection products such as Nipah and Hendra or drugs for preventing and treating Nipah and Hendra virus diseases.

The application provides an autoantibody marker for predicting the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, a series of autoantibody marker molecules are screened by detecting autoantibodies against different antigen targets in blood of lung cancer patients in the third stage, and the autoantibody marker molecules have great correlation with the prediction of the effect of lung cancer immunneoadjuvant therapy, and three autoantibody biomarkers with better prediction of the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage are further screened by combining with a CART decision tree strategy; the combination of the autoantibody biomarkers can be used for efficiently predicting whether the lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage is effective, providing a reference basis for a clinician to decide a treatment scheme, providing a new prediction means for the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, and having important scientific significance and clinical application value.

The invention discloses a hepatocellular carcinoma prognosis and treatment adaptability evaluation model based on mRNA vaccine antigen and a construction method. The method comprises the following steps: firstly, analyzing gene expression difference between normal tissues and hepatocellular carcinoma tumors, understanding mutation and genome structure change of hepatocellular carcinoma patients, and then further selecting genes related to the infiltration level of antigen presenting cells from abnormally expressed genes and mutant genes, and the genes having a significant relationship with the overall lifetime and disease-free lifetime of the patient, so as to obtain candidate mRNA vaccine neoantigen targets. Based on the expression level of the target, immunotyping is performed on the patient, and the patient population suitable for the mRNA vaccine is evaluated. Meanwhile, the relationship between the expression level of the target spot and the prognosis of the patient is quantified, so that the probability value that the total survival time of the hepatocellular carcinoma patient reaches 3 years and 5 years is predicted. According to the invention, the hepatocellular carcinoma treatment resistance and tumor immune state can be objectively and accurately evaluated, and the prediction accuracy of hepatocellular carcinoma treatment prognosis is improved.

The application discloses an anti-RAGE antibody, which can target RAGE antigen targets of different species such as human, murine and monkey. The application further discloses a conjugate, a bispecific antibody, a multispecific antibody, an immune cell, and a fusion protein which respectively comprises the anti-RAGE antibody, and further discloses a method for displaying the anti-RAGE antibody on extracellular vesicles. The anti-RAGE antibody provided by the application is applied to display on extracellular vesicles, endowing the extracellular vesicles with targeting ability, and finally enriching the extracellular vesicles in specific lesion tissues or organs with high expression of RAGE antigens, thereby facilitating the delivery, release and therapeutic effects of other drug molecules loaded on the extracellular vesicles in the specific lesion tissues.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The present invention belongs to the field of animal vaccines, and specifically relates to a multi-epitope fusion protein of Gramseria parasuis antigens targeting multiple serotypes and its application. The applicant conducted proteomic analysis on four clinical isolates of Gramseria parasuis serotypes 4, 5, and 13 with high virulence and good immunogenicity, and screened out 8 antigenic proteins. The 8 screened antigenic proteins were further analyzed, and finally an immunogenic multi-epitope fusion protein of antigens that can recognize the three serotypes was obtained. As a vaccine, the fusion protein achieved a 100% protection rate against piglets infected with the clinically isolated serotype 4 strain HB04, the serotype 5 strain SJZ05, and the serotype 13 strain GD20.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The application provides a self-assembled ferritin nanovaccine targeting tuberculosis subunit antigens and a preparation method and application thereof, and belongs to the technical field of biological medicines. The application provides a subunit nanoparticle, selects ESAT-6 (E6), CFP-10 (C10) and ESAT-6-CFP-10 (EC) proteins as antigen target points, takes ferritin as a potential presentation carrier of TB epitope target points, fuses the E6, C10 and EC antigens into the ferritin, successfully self-assembles into a uniform epitope nanovaccine, has better immunogenicity, and can trigger a high-efficiency cellular immune response and immune memory. The application also uses an expression system method to complete expression and production of the subunit nanoparticle, and has economy and is suitable for large-scale production.

This invention relates to recombinant mammalian cells and their use in treating cancer. The present invention specifically relates to the co-expression of an adapter CAR and a conventional CAR in CAR T cells and the use of these cells in treating lymphoma. The invention also relates to pharmaceutical compositions comprising such recombinant mammalian cells, as well as their uses in cancer therapy.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

The present invention provides protective monoclonal antibodies targeting Nipah virus (NiV) G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out two monoclonal antibodies LN1F9 and LN1D11 that can specifically bind to NiV G protein. In vitro neutralization experiments have shown that these two antibodies have high neutralizing activity against both NiV-M and NiV-B strains, among which LN1F9 can also neutralize Hendra virus (HeV) of the same genus. The monoclonal antibodies LN1F9 and LN1D11 can effectively treat hamsters infected with NiV and prevent NiV infection in hamsters. They have extremely high application value in clinical treatment and prevention of NiV and HeV infection, and can be used to prepare detection products and preventive and therapeutic drugs for NiV and HeV.

The present invention relates to a dual antigen-targeting protein complex comprising an antibody or its antigen-binding fragment and an affibody. More specifically, the dual antigen-targeting protein complex comprises an EGFR (Epidermal Growth Factor Receptor) or PSMA (Prostate Specific Membrane Antigen) target site containing an antibody or its antigen-binding fragment, and a CD137 target site containing an affibody bound to the antibody or its antigen-binding fragment. When the dual antigen-targeting protein complex or a composition containing it is used, cancer can be effectively prevented or treated.

Anti-EphA2 antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-EphA2 antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making the same are also disclosed.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

This invention discloses an environmental detection method for underwater multi-autonomous robotic fish. First, an interconnected, coupled, immune-cooperative detection model of underwater multi-autonomous robotic fish is constructed and its parameters are initialized. The robotic fish acquires environmental information about surrounding obstacles and the detected area, and identifies the original antigens of the obstacles. E o and the original antigens in the detected areas E d The invention identifies the decomposition antigens targeting obstacles and detected areas, thereby determining the antibody concentrations of the robotic fish and selecting antibodies based on these concentrations. Based on the behavior of the selected antibodies, the robotic fish completes the next step of detection until the entire detection process is finished. This invention uses the robotic fish's environment as an antigen, the robotic fish as a B cell, and its behavior as antibodies. It constructs an interconnected and coupled immune collaborative detection network targeting obstacles and detected areas, achieving a balance in the robotic fish's processing of two types of environmental information. This improves the coverage of environmental detection, reduces detection duplication, and enables the robotic fish to move rapidly and effectively in unknown and complex environments, thus improving detection efficiency.

The present disclosure provides linker-payload conjugates including a cysteine-reactive group and a hydrophilic moiety. The improved linker-payloads for biomolecules conjugation and improved drug conjugates exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. cMET, HER3, EGFR, TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

The invention discloses a colloidal gold immunochromatography test strip for saliva sample detection and a preparation method thereof.The test strip comprises a supporting layer, and a sample pad, a combination pad, an NC membrane and a water absorption layer are sequentially arranged on the supporting layer from the sample introduction end; at least partial areas of the sample pad and the combination pad are obtained by drying after being pretreated by saliva sample treatment liquid, and the saliva sample treatment liquid comprises the following components: a zwitterionic anti-adsorption buffer system, an antibody conformation relaxation agent, a chelating agent type colloid redispersant, hydrophilic small molecular protein and a cyclodextrin type hydrophobic shielding agent. According to the method, systematic improvement is performed from the biochemical performance of the sample and the state of the antigen target, so that the defects that the target is covered by the colloidal environment of saliva and the target is lost due to aggregation of the target antigen are effectively overcome, and the detection sensitivity is greatly improved.

Anti-Met antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-Met antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making same are also disclosed.

The application discloses an antibody conjugated drug binding prediction method based on a virtual graph and multi-scale features, proposes a drug carrier, a linker, an antibody heavy chain and a light chain, and an antigen target protein initial feature construction method, proposes a 1DCNN for extracting drug sequence features, designs a drug feature extraction method based on a graph virtual node, introduces a virtual node and a virtual edge into a molecular structure graph, takes a Graph Transformer as a graph feature extractor, takes a virtual node feature as a drug representation, then inputs protein and drug features into a feature fusion module, adds an attention mechanism and a gated skip connection mechanism in feature fusion, captures potential interactions while fusing feature information of different hidden layers, and realizes higher precision affinity prediction. The application can solve the technical problems that existing methods are difficult to extract structural features of antibody conjugated drugs and features of different components are difficult to fuse.

The invention discloses an oral vaccine as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The oral vaccine comprises a core, and a permeation enhancing layer, an active molecular layer and an enteric coating layer which are sequentially coated on the surface of the core, the core is a biodegradable polymer nano particle; the permeation enhancing layer is a polydopamine layer loaded with a permeation enhancer; the active molecular layer is a chitosan layer loaded with an antigen and a targeting substance. The oral vaccine provided by the embodiment of the invention is good in stability, can ensure that the antigen is stable in gastrointestinal tracts and keeps activity, realizes targeted release of intestinal tracts, can activate far-end mucous membrane tissues at the same time, realizes broad-spectrum IgA and IgG immunization, and is suitable for delivery of various oral antigens.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.

The present disclosure relates to combinations of tumor-targeted IL2 receptor agonists and multispecific T-cell engagers, e.g., for use in stimulating T-cells against cancer cells or treatment of cancer. The tumor-targeted IL2 receptor agonists comprise a tumor-associated antigen targeting moiety and an IL2 moiety. The multispecific T-cell engagers comprise a tumor-associated antigen targeting moiety and a T-cell receptor complex targeting moiety.

To provide acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.SOLUTION: There is provided an isolated immunoresponsive cell comprising (a) a first chimeric receptor comprising an extracellular antigen-binding domain that binds to a first antigen, and (b) a second chimeric receptor comprising an extracellular antigen-binding domain that binds to a second antigen, wherein each antigen is selected from a group consisting of FLT3, CD33, CLEC12A, MS4A3, VSTM1, LAT2, MLC1, CD131, GAPT, PRAM1, SLC22A16, SLC17A9, SPNS3, ADGRE2, IL3RA, CD117, CD93, IL1RAP, CD244, CCR1, LILRB2, PIEZO1, CD38, EMB, MYADM, LILRA2, CD300LF, and CD70, and wherein the first antigen is different from the second antigen.SELECTED DRAWING: Figure 1

The present invention provides a multispecific polypeptide construct comprising: (a) one or more antigen targeting domains that bind to one or more tumor-associated antigens; and (b) one or more NK cell targeting domains, wherein binding to NK cells may stimulate and / or inhibit innate immune cell function. Also disclosed are antigen binding proteins or antigen binding fragments thereof; a nucleic acid sequence; a carrier; a host cell; methods of making multispecific polypeptide constructs or antibodies; methods of screening and / or identifying multispecific polypeptide constructs or antibodies as disclosed herein; a pharmaceutical composition; and methods of treating cancer.

In one aspect, the disclosure relates to analogs of EBC-46. In one aspect, the analogs are modulators of protein kinase C (PKC). In another aspect, the disclosed compounds can be used in the treatment of solid tumors, HIV / AIDS, and neurodegenerative diseases, as well as in the enhancement of antigen density in antigen-targeted CAR-T and CAR-NK cell immunotherapies. In yet another aspect, the disclosed compounds are selective for individual PKC isoforms, allowing precise targeting of diseases associated with PKC dysfunction. In an alternative aspect, the disclosed compounds are useful as pan-PKC modulators and are not selective. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to CAR-expressing immune cells for improving cancer treatment and immunotherapy efficacy. More specifically, the present invention provides immune cells expressing a bispecific CAR (biCAR) that targets both endoglin and mesothelin, and thus is expected to be used as an immunotherapeutic agent capable of reducing immunosuppression by CAF in a tumor microenvironment and effectively killing cancer cells.

An Echinococcus granulosus antigen Eg73 and its encoding gene and application belong to the field of immunology technology. The present invention utilizes a three-day-old Echinococcus granulosus larvae cDNA expression library to screen the Eg73 antigen protein in a high-throughput, unbiased manner, and further provides a method for preparing the antigen protein and its application, aiming to provide a new antigen target for the development of candidate antigens for canine anti-Echinococcus granulosus vaccines. This solves the current problem of stagnant vaccine development for canine anti-Echinococcus granulosus infection and lagging protective antigen screening. The amino acid sequence of the antigen protein is shown in SEQ ID NO.6, and the nucleotide sequence encoding the antigen protein is shown in SEQ ID NO.7. It has been verified that the antigen protein can specifically react with positive serum from dogs infected with Echinococcus granulosus, and has high application value in the research and development of canine anti-Echinococcus granulosus vaccines and diagnostic reagents.

This invention discloses a method for preparing a nanozyme-antibody complex based on site-directed enzyme catalytic coupling, its products, and applications, belonging to the field of nanomedicine technology. The preparation method of this invention involves the site-directed introduction of an azide group at the Fc segment of the antibody's glycan chain through a cascade catalysis of N-glycosidase (PNGase F) and transglutaminase (TGase). Then, a click chemistry reaction is carried out between a platinum nanozyme modified with a DBCO group and the azide group, thereby constructing a nanozyme-antibody conjugate complex consisting of a single antibody coupled with two platinum nanozymes. During the coupling process, the structural integrity of the antibody and its antigen-targeting recognition function are maintained to the greatest extent, and the complex possesses highly efficient enzyme-like catalytic activity and good environmental stability, significantly improving the efficiency of converting the concentration information of the target substance into a color signal.